Among matrix metalloproteinases (MMPs), gelatinases MMP-2 (gelatinase A) and MMP-9 (gelatinase B) play a key role in a number of physiological processes such as tissue repair and fibrosis. Many evidences point out their involvement in a series of pathological events, such as arthritis, multiple sclerosis, cardiovascular diseases, inflammatory processes and tumor progression by degradation of the extracellular matrix. To date, the identification of non-specific MMP inhibitors has made difficult the selective targeting of gelatinases. In this work we report the identification, design and synthesis of new gelatinase inhibitors with appropriate drug-like properties and good profile in terms of affinity and selectivity. By a detailed in silico protocol and innovative and versatile solid phase approaches, a series of 4-thiazolydinyl-N-hydroxycarboxyamide derivatives were identified. In particular, compounds 9a and 10a showed a potent inhibitory activity against gelatinase B and good selectivity over the other MMP considered in this study. The identified compounds could represent novel potential candidates as therapeutic agents.
Introduction
Matrix metalloproteinases (MMPs) are a family of approximately 27 zinc-dependent endopeptidases, involved in the proteolytic processing of several components of the extracellular matrix (ECM), such as collagen, proteoglycans and fibronectin.
In the last decades, considerable evidences have highlighted the involvement of abnormal MMP expression in several pathological conditions. In particular, MMP-2 and MMP-9, main enzymes able to degrade type IV collagen and gelatin, have been demonstrated to be directly involved in endothelial cell migration and vascular remodeling during angiogenesis, in tumor cell growth and progression during metastasis.
In the last twenty years, the blockage of the extracellular matrix degrading activities of MMPs has been considered an attractive strategy to treat a broad spectrum of diseases including cancer, neurological diseases, arthritis and cardiovascular pathologies. [1] [2] [3] Moreover, although several potent MMPIs have been discovered, 4 -8 the serious dose-limiting side effects occurring in clinical trials, [9] [10] [11] probably due to the non-selective inhibitory activity, have underlined the importance to identify novel inhibitors able to discriminate among MMPs. 12, 13 In this scenario, the selective inhibition of gelatinases may provide confidence for a successful clinical trial, targeting acute cardiovascular diseases and tumor progression. [14] [15] [16] In particular MMP-2 is considered to be a better candidate target for anticancer drugs than MMP-9, whose inhibition is related to greater drug side effects. 17, 18 In this paper we describe the identification of novel and selective gelatinase inhibitors by an in silico rational drug design approach and a versatile solid phase synthetic strategy. Starting from the MMP-2 complexes available in the Protein Data Bank (PDB), 19 an active site mapping of gelatinase A was performed to generate the pharmacophore model used for the in silico screening of our in-house small molecule database. The screening was then followed by rational compound selection based on criteria, such as physico-chemical properties, ADMET predictions and synthetic feasibility. The computational approach led to the identification of the pyroglutamic moiety ( Fig. 1 ) as a promising scaffold for the design and optimization of novel gelatinase inhibitors. By rational structure optimization, 4-thiazolydinyl-N-hydroxycarboxyamide selected SC-74020 NMR conformation was used to develop a pharmacophore model to mine novel and potential gelatinase inhibitors from our in-house virtual database, named MoDa. As shown in Figure 3 , we considered two key pharmacophoric features: the ZBG and the P 0 1 moiety, which represent the two known binding and stabilizing interactions with the molecular target. In order to identify new scaffolds to be used for further investigations and deeper modifications, no further features were included to describe the long P 0 1 group.
2D-and 3D-database generation
About 2 million unique commercially available small molecules have been collected in a proprietary 2D small molecule database, namely MoDa (Molecular Database). By using MOE, drug-like filters were applied to remove non drug-like, toxic or reactive molecules. [22] [23] [24] Finally a number of around 600,000 unique structures were selected and for each molecule the 3D coordinates were derived. After energy minimization, for each 3D structure, a set of representative conformers was generated by molecular dynamic simulations. Low-energy conformations (65 kcal/mol from the global minimum) were included in the conformer database with a limit of 70 conformers per molecule, for the most flexible structures.
Pharmacophore based virtual screening
The derived 3D database was screened in MOE against the pharmacophore model. Hit compounds were ranked according to the score value defined by the RMSD of the aligned pharmacophoric points onto the pharmacophore model: no overlap on the excluded volume was permitted and, finally, about 200,000 molecules were identified. In order to select a more restricted number of compounds to be assayed against gelatinases, the selection was limited to a set of compounds bearing classical zinc binding groups (ZBG) such as carboxylic and hydroxamic acids. A molecular weight limit of 300 Da was imposed and a set of 150 compounds was obtained. Virtual hits were then visually inspected and selected following two criteria: synthetic feasibility and easiness to perform chemical modifications. Among the hit list, 15 compounds were selected, purchased, and assayed. The virtual screening flowchart is summarized in Figure 4 , while the most representative compounds are depicted in Figure 5 .
Among the screened compounds, the pyroglutamic acid derivative (S)-1 0 b showed an in vitro MMP-2 inhibitory activity in the micromolar range (IC 50 = 315 lM), prompting us to consider it 
Chemical modification on selected scaffold
A first series of chemical modifications were performed on (S)-1 0 b template in order to investigate the influence on gelatinase inhibitory activity of (1) halogen position on the aromatic ring, (2) benzene ring replacement with a well-fitting P 0 1 substituent (biphenyl moiety), (3) introduction of a non-carboxylic acid ZBG (hydroxamic acid or amide group) and (4) chirality. These compounds were synthesized according to Schemes 1 and 2 and biologically screened against MMP-2 and MMP-9 ( Table 1) .
The biological data confirmed the expected results in terms of best ZBG and P 0 1 residues, while no significant effect of stereochemistry at C5 position was recorded. The in vitro screening led us to the identification of several hits and one of which, (S)-1a, was selected as the most versatile and promising hit, with a IC 50 equal to 9 and 144 lM on MMP-2 and MMP-9, respectively.
Hit to lead
In order to improve gelatinase inhibitor potency, different chemical modifications were performed on the (S)-1a pyroglutamate moiety, keeping the ZBG and P 0 1 groups unchanged (Fig. 6 ) and evaluating chemical modifications on the five-membered ring and the methylene group. The pyroglutamate ring was replaced with commercially available proline (2a), thiazolidine (3a) and hydroxyproline (4a). Thiazolidinone derivative 5a was synthesized to investigate the influence of both the carbonyl group and the sulfur atom on the ring. Moreover, we synthesized the sulfonamide derivatives of pyroglutamate (6a), proline (7a), and thiazolidine (8a) since several literature data reported aryl-sulfonamide substituents to be the most favorable ones. 25 All novel compounds were synthesized (Scheme 3-6) and tested against gelatinases (Table 2 ). SAR analysis suggested that the introduction of a polar group, such as a carbonyl moiety at Y, maintaining a methylene group at Z position, strongly increases the inhibitory potency (i.e., 1a vs 2a; 5a vs 3a). Nevertheless, when the methylene group in Z is replaced with the SO 2 function, the influence of the carbonyl moiety in Y is negligible (i.e., 6a vs 7a). In contrast, the SO 2 group in Z enhances the positive effect of the substitution in the X position with a sulfur atom (compare compounds 2a/3a, 1a/5a and 7a/8a). We identified compound 8a as lead compound, with an IC 50 value of 200 nM and of 230 nM towards MMP-2 and MMP-9, respectively. In order to get a more detailed representation of the recognition features, the compound was docked into the binding site of MMP-2 crystal structure. The results revealed that compound 8a adopts the expected binding mode with P 0 1 moiety involved in hydrophobic interactions with S 0 1 residues, giving high docking score in according with experimental data (data not shown).
8a scaffold optimization
From compound 8a further modifications were performed on P 0 1 group. Several 8a analogues bearing different bulky groups in R position were synthesized, most of them being related to known and potent MMP inhibitors. Furthermore, the effects on the biological activity of the -S-substitution on the five-membered ring with sulfoxide and sulfone moiety were evaluated.
All the compounds were synthesized and tested against MMP-2 and MMP-9 (Table 3) . According to the biological data, the substitution of the biphenyl moiety with more rigid groups, such as naphthalene or quinoline, dramatically decreases the inhibitor activity on both gelatinases (i.e., 8h and 8i), while, as expected, a relevant 20-fold improvement occurs upon substitution of the biphenyl ring with a para-substituted diaryl ether (see compounds 8j, 8k, 8l in Table 3 ).
Subsequently, the accomplishment of a further improvement in inhibitory activity and a good degree of selectivity between the two gelatinases were achieved through substitution of -S-by -S(O) n -(where n = 1 or 2, see compound 9a and 10a in Table 3 ).
To underline the selectivity profiles over other MMPs, the most promising compounds were tested against a broader panel of MMPs (Table 4) .
Compounds 8k and 8l exhibited a relevant rate of discrimination with respect to MMP-1 and MMP-3. Moreover, compounds 9a and 10a showed a significant MMP-2 selectivity even over MMP-9. Unfortunately, more the activity increases, more the selectivity fades out. In addition, data collected for compound 10k (Table 4) show that when gelatinase activity is in the low nanomo- 
In silico investigation of MMP-2 selectivity over MMP-9
To investigate the different activity of 9a and 10a towards the two gelatinases, docking analysis on MMP-9 and MMP-2 binding sites was performed (see Section 5 for details). The comparison of the best scored solutions of both molecules highlighted a different binding mode in the two protein binding sites. For instance, visual inspection of 10a binding mode (Fig. 7) revealed that one oxygen atom of the sulfonamide group can form an hydrogen bond with the NH group of MMP-9 Gln402 side-chain while in MMP-2 the hydroxamic NH group is involved in a hydrogen bond with the backbone of Ala165. The most remarkable difference in the binding modes of the two inhibitors relies on a significant change of overall shapes of the two heterocyclic rings in the two gelatinases. In MMP-2 binding site, one oxygen of the endocyclic SO 2 /SO is involved in an hydrogen bond with the NH group of Ala164 backbone, while in MMP-9 the same group does not give further interactions, leading to a lower docking score (10a: 82.01 and 69.70, respectively). The lack of this additional favorable interaction is probably due to the presence of a larger S 0 1 pocket that forces the molecules to plunge in deeply.
Solid phase synthesis
A versatile solid phase strategy for the synthesis of scaffolds 1-8 was developed.
In order to obtain compounds 1-1 0 -1 00 a-c we performed a new synthetic solid phase approach using either a NovaSyn Tentagel resin or a Rink amide resin depending on whether the final cleavage should release a carboxylic/hydroxamic or an amidic moiety (Scheme 1 and 2). Both enantiomers of Fmoc-protected amino acid 11 were commercially available in pure enantiomeric form. Attachment to the resin followed by deprotection of the Fmoc group and subsequent reductive amination with appropriate alkylating reagents provided N-alkylated compounds 13-16a-c. Removal of the protective group easily allowed condensation of the pyroglutamic ring to obtain 14-17a-c. Final cleavage from the resin gave compounds 1-1 0 -1 00 a-c with good purity degree (>90% by HPLC-MS). Table 1 Gelatinase A and B inhibitory activity of (R)-and (S)-1 derivatives To obtain compounds 2a, 3a and 4a Fmoc protected hydroxylamine was tethered to 2-chloro-chlorotrytil resin, which proved to be suitable to ensure the final release of hydroxamic derivatives (Scheme 3). After removal of the Fmoc group, coupling of compound 19 with Fmoc-protected proline/thioproline/hydroxyproline-carboxylic acids 20-22 gave compounds 23-25. Fmoc group was then cleaved and subsequent reductive amination with p-phenylbenzaldehyde and cleavage from the resin released 2a, 3a and 4a in good yields.
An innovative strategy was developed to obtain the oxothiazolidine hydroxamate derivative 5a (Scheme 4). The compound was conveniently synthesized starting from Fmoc protected (R)-2-amino-3-(tritylthio)propanoic acid 29. The substrate was anchored on NovaSyn Tentagel resin and after Fmoc cleavage reductive amination with p-phenylbenzaldehyde was performed. Compound 31 was then deprotected, cyclized, and cleaved from the resin to give compound 5a.
An original pattern was then envisaged to synthesize compound 6, which maintained the same ZBG and P 0 1 substituent as 5a, changing the thiazolidinone ring into a pyrrolidonone (Scheme 5). Carboxylic acid (S)-11 was converted to hydroxamic acid (S)-33 and anchored on 2-chloro-chlorotrytil resin to obtain (S)-34. Then, Fmoc deprotection followed by sulfonamide synthesis gave (S)-35. Ring closing reaction occurred using the same conditions applied to synthesize derivatives 13 and 16 after acid deprotection (Scheme 1 and 2). Final cleavage from the resin using TFA produced 6 with high purity.
Compounds 7a, 8a, 8h-l, 9a, 10a, 10k were obtained only from two building blocks 20 and 21 (Scheme 6). NovaSyn Tentagel resin was chosen to tether the two acids. After Fmoc cleavage the amino group was reacted with several sulfonyl chlorides to obtain sulfonamides 39a and 40a, h-l.
Compounds 39a and 40h-l were immediately released from the resin to give 7a and 8h-l, while 40a was split into two different batches. The first batch was used to give 8a, the second one was oxidized with MCPBA, so to introduce a sulfone moiety on the ring to give 41a. Compound 41a was again split in two in order to obtain 9a and perform the oxidation of sulfone to sulfoxide to finally release 10a.
Conclusion
In conclusion, a pharmacophore based virtual screening of our in-house database and further chemical optimization led us to design novel gelatinase inhibitors. The compounds were synthesized developing and applying a solid phase approach. Docking simulations were performed to study the possible motifs of selectivity between MMP-2 and MMP-9. Notably, a very interesting selectivity was observed for some compounds with good in silico drug-likeness profile. In particular the 4-thiazolydinyl-N-hydroxycarboxyamide derivatives 9a and 10a showed a MMP-2 inhibitory activity in the low nanomolar range and a good selectivity over the MMPs analysed in this study. The achieved results represent a good starting point for future research activities, directed toward further medicinal chemistry optimizations. 
. MoDa-2D database
MoDa is a web-based application developed using the Perl programming language, containing about 2 millions distinct molecules from about 9 millions commercially available compounds. MoDa uses MySQL as Relational Database management System and Apache as web server.
MoDa-3D database
By using MOE, the compounds were selected from the MoDa-2D database according to the drug-like criteria, by property descriptor calculation, which include: number of violations of the Lipinsky's rule of five and other drug-like filters such as number of rings, number of halogens and undesirable reactive groups. A subset of about 600,000 compounds were selected and used to generate a database of conformers. The conformational analysis search was carried out via molecular dynamic (MD) as implemented in the MOE software package. For each compound, an MD run of 1 ns was performed using the NVT ensemble with T = 300 K, time step of 0.002 ps using MMFF94 force field and the Born solvation model. A total of 1000 conformations were collected for each MD run and they were energy-minimized requiring a RMSD of the gradient less than 0.05 kcal/mol.
Pharmacophore design
MOE Pharmacophore Applications module has been used to design pharmacophore hypotheses and to perform database screening. The PCH pharmacophore scheme included the following atomic tags: H-Bond Acceptor, H-Bond Donor, Cation, Anion, Aromatic ring center, Hydrophobic Region, Metal Ligator, Volume Constraint. In detail, by using SC-74020 ligand coordinates as reference template, the first pharmacophoric point was fixed on hydroxamic group setting a tolerance radius of 1.8 Å to include one or both oxygen atoms of alternative other ZBGs (e.g. carboxylic acids, hydroxamic acids, phosphates). The second pharmacophoric point was defined on the P 0 1 phenyl group, with a tolerance radius comparable with the size of an aromatic ring (1.8 Å). Finally, the overall shape of the protein around the catalytic site and the S of SC-74020. Around 200 atom points were used to describe the excluded volume in such a manner that also larger inhibitors should satisfy the same query (Fig. 3b) .
Docking simulations
In the present study, the 3D coordinates of MMP-2 and MMP-9 (pdb codes: 1qib and 2ow1, respectively) were retrieved from the PDB. Protein preparation was performed in MOE: the two proteins were aligned, the water molecules, cofactors and (MMP-9) cocrystallized ligand were removed; by using Protonate 3D tool, the hydrogen atoms were added, fixing the correct protonation of protein residues. The inhibitors described in this work were built from the MOE fragment library and minimized by setting MMFF94 force field.
Docking simulations were performed using the GOLD program (Cambridge Crystallographic Data Centre, Cambridge, UK) by setting the GoldScore (GS) fitness functions to quantify the interaction energy of ligand-protein complexes. The fitness function parameters were taken from the GOLD parameter file. The binding cavities contained the protein residues in a sphere of a 12 Å radius centred on the SC-74020 aromatic carbon C18. Zinc trigonal/bipyramidal coordination geometry was imposed. For each compounds, 10 poses were generated into the binding site of MMP-2 and MMP-9, respectively. The binding mode inspections were carried out by Hermes Viewer implemented in GOLD software.
Additional softwares
Visual inspections of docking and pharmacophore analysis were performed with PyMOL. 26 In addition MOE, Babel, CDK and JOELib were used as chemoinformatic tools for SMARTS search, conversion, and other routine tasks.
Chemistry
Reagents and solvents were obtained from commercial suppliers and used without further purification. Thin layer chromatography (TLC) analytical separations were conducted with E. Merck Silica Gel F-254 plates of 0.25 mm thickness and were visualized with UV light (254 nm) or I 2 . Flash chromatography was performed using E. Merck silica gel.
H nuclear magnetic resonance (NMR)
spectra were recorded in the specified deuterated solvents on a Bruker Avance 300 spectrometer operating at 300 MHz. Chemical shifts are reported in parts per million (d) from the tetramethylsilane resonance in the indicated solvent (TMS: 0.0 ppm). Compounds purities and mass spectra were determined by an LC/MS platform (Gilson/ThermoFinnigan) using the positive electrospray ionization technique (+ES) with a mobile phase of acetonitrile/ water with 0.1% TFA.
Elementary analyses were performed on a Perkin-Elmer 2400 Series II Elemental Analyser and a microbalance AD-4 autobalance Perkin-Elmer.
Optical rotations were determined at 25°C on a Perkin-Elmer 341 polarimeter (concentrations are reported in units of grams per 100 mL).
General methods for solid phase synthesis
Solvents were distilled for resin reactions. Unless otherwise stated reactions were performed in 8 mL polypropylene cartridges with 70 mm PE frits. Cartridges and stopcocks were obtained from Applied Separations. All Fmoc amino acids, coupling reagents, and resins were purchased from Novabiochem, and other chemicals were from Aldrich.
General procedures for coupling of Fmoc-(D/L)-Glu-(OAll)-OH to NovaSynTGOH
Example: Synthesis of (R)-12. N,N 0 -Diisopropylcarbodiimide (DIC) (300 ll, 1.9 mmol) was added to a solution of Fmoc-D-Glu-(OAll)-OH (R)-11 (1.55 g, 3.8 mmol) in 10 ml dry DCM at 0°C. After stirring at room temperature for 1 h, DCM was evaporated, 3 ml of DMF were added and the solution was dropped into the cartridge in which hydroxyl group functionalized resin (NovaSynTGOH) (1.26 g, 0.38 mmol) was pre-swollen in DCM. 4-Dimethylaminopyridine (DMAP) (5 mg, 0.04 mmol) in 0.3 ml dry DMF was introduced and the cartridge was gently rocked for 2 h at room temperature. After filtration the resin was rinsed with DMF (3 Â 5 ml), DCM (3 Â 5 ml) and TBME (3 Â 5 ml) and finally dried in vacuo.
The efficiency of loading (loading yield: 81%) was determined on 5.9 mg of resin by Fmoc removal analysis (treatment of the resin with piperidine 20% in DMF) and absorbance measurement at 301 nm (UV-vis Spectrophotometer Shimadzu).
General procedures for Fmoc deprotection and reductive amination of polymer bound O-All-(D/L) glutamate
Example: Synthesis of (R)-13a. After Fmoc deprotection with 20% piperidine in DMF for 20 min (Â2), (R)-12 (0.08 mmol) was washed (2 Â DMF, 2 Â DCM) and swollen in DCM, then biphenyl-4-carboxaldehyde (120 mg, 0.66 mmol) in 0.8 ml trimethyl orthoformate (TMOF) was added dropwise. Subsequently methanol (MeOH) (200 ll), acetic acid (38 ll, 0.66 mmol) and NaCNBH 3 (124 mg, 1.97 mmol) in MeOH (400 ll) were respectively introduced into the reaction mixture.
After shaking for 1 h at room temperature, the resin was filtered and washed with MeOH (Â3), DMF (Â3), DCM (Â3) and TBME (Â3).
General procedures for allyl deprotection and cyclization
Example: Synthesis of (R)-14a.
PhSiH 3 (500 ll, 4.1 mmol) and Pd[P(Ph) 3 ] 4 (95 mg, 0.08 mmol) in 2 ml dry DCM were added to 0.08 mmol of (R)-13a pre-swollen in DCM. 10 ± 2 5 ± 0.5 >50,000 700 ± 100 ND ND ND 9a 9 ± 3 600 ± 100 4000 ± 500 2000 ± 300 400 ± 100 2500 ± 500 160 ± 20 10a 53 ± 16 480 ± 80 2500 ± 100 4000 ± 100 100 ± 40 500 ± 10 3800 ± 500 10k 0.8 ± 0.1 0.5 ± 0.07 ND ND 4 ± 1 19 ± 6 5 ± 0.5
After repeating the treatment twice (2 Â 5 min) the resin was filtered, rinsed first with DCM, and later with a solution of DIEA (0.5%) and NaEt 2 NCS 2 (0.5%) in DMF, and again with DMF, DCM and DMF.
DIEA (17 ll, 0.01 mmol) and a solution of HATU (2-(1H-9-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (38 mg, 0.01 mmol) previously dissolved in 0.7 ml of dry DMF were introduced into the cartridge; the cyclization proceeded for 3 h at room temperature. The resin was filtered and rinsed with DMF (Â3), MeOH (Â3), DCM (Â3) and TBME (Â3).
General procedures for the cleavage of hydroxamate derivatives 1
Example:
Functionalized resin derivative (R)-14a (0.04 mmol) was swollen in THF (1.8 ml) and cleaved from the solid support by treatment with 50% NH 2 OH in H 2 O (300 ll, 5.6 mmol). After rocking for 5 h at room temperature, the resin was filtered and the filtrate was evaporated to dryness.
The crude product was further purified by semi-preparative RP-HPLC (C18, Nucleosil 300 mm Â 25 mm, 3 ml/min, detection at 230 nm, eluent A: Water/TFA: 99.92:0.08, eluent B: acetonitrile/ TFA: 99.92:0.08; gradient B from 20% to 80% in 14 min, from 80% to 98% in 3 min) to afford (R)-1a.
Amorphous 
(R )-1c: (R)-1-(4-Chlorobenzyl)-N-hydroxy-5-oxopyrrolidine-2-carboxamide.
Example: (R)-1-(4-phenylbenzyl)-5-oxopyrrolidine-2-carboxylic acid [(R)-1
0 a]. Functionalized resin derivative (R)-14a (0.04 mmol) was swollen in THF (1.8 ml) and cleaved by NaOH 0.5% solution (2.5 ml, 0.37 mmol). After rocking for 1.5 h at room temperature, the resin was filtered and the filtrate was evaporated to dryness.
Deprotected (R)-1 0 a was purified by semi-preparative RP-HPLC (C18, Nucleosil 300 mm Â 25 mm, 3 (130 ll, 1.18 mmol) in 1 ml dry DMF was introduced into the cartridge. After stirring at room temperature for 2 h, the resin was filtered, rinsed with DMF (3 Â 5 ml), DCM (3 Â 5 ml) and TBME (3 Â 5 ml) and finally dried in vacuo.
A positive Kaiser test 27 resulted, indicating no free amine groups on the resin.
General procedures for Fmoc deprotection and reductive amination of polymer bound O-all-glutamate
The same procedure described for NovaSynTGOH bound derivatives (Synthesis of (R)-13) was followed.
General procedures for synthesis of polymer bound pyroglutamate ring
The same procedure described for NovaSynTGOH bound derivatives (synthesis of (R)-14a) was followed. After rocking for 1 h at room temperature, the resin was filtered and the filtrate was evaporated to dryness.
The crude compound (R)-1 00 c did not need further purification as shown by HPLC-MS analysis (97% of pure compound at 220 nm; 88% at 254 nm). 
General procedures for loading Fmoc-NHOH on chlorotritylresin
Example: Synthesis of 19.
A solution of Fmoc-NHOH (51 mg, 0.2 mmol) and DIPEA (70 ll, 0.4 mmol) in 2 ml DCM was dropped on chlorotrityl resin (Novabiochem) (0.2 mmol) pre-swollen in DCM. 28 After shaking for 60 h at room temperature, the resin was filtered and rinsed with DCM (3 Â 5 ml) DMF (3 Â 5 ml), DCM (3 Â 5 ml) and TBME (3 Â 5 ml) and finally dried in vacuo.
The efficiency of loading (loading yield: 53%) was determined on 3 mg of resin by Fmoc removal analysis (treatment of the resin with piperidine 20% in DMF) and absorbance measurement at 301 nm (UV-vis Spectrophotometer Shimadzu).
General procedures for coupling of proline/thioproline/ hydroxyproline rings to -NHOH functionalized resin
Example: Synthesis of 23.
A solution of Fmoc-L-proline (0.34 g, 1 mmol), HATU (0.38 g, 1 mmol), and DIPEA (348 ll, 2 mmol) in 2 ml of dry DMF/DCM
(1:1) was added dropwise on the functionalized resin 19 (0.2 mmol) after Fmoc deprotection via classical procedure (20% Piperidine in DMF for 20 min (Â2)). The cartridge was shaked for 12 h at room temperature. After filtration the resin was rinsed with DMF (3 Â 5 ml), DCM (3 Â 5 ml) and TBME (3 Â 5 ml) and finally dried in vacuo.
General procedures for Fmoc deprotection and reductive amination on polymer bound proline/thioproline/ hydroxyproline rings
The same procedure described for the synthesis of (R)-13 was followed.
General procedures for cleavage of hydroxamates derivatives 2a, 3a, 4a
Example: Synthesis 2a.
After swelling functionalized resin 26, the crude product 2a (0.1 mmol) was cleaved by treatment with 2 ml of AcOH/TFE/ DCM (1:1:8) for 1 h at room temperature. The resin was filtered and the filtrate was evaporated under N 2 .
The crude product 2a was further purified by semi-preparative RP-HPLC (C18, Nucleosil 300 mm Â 25 mm, 3 ml/min, detection at 230 nm, eluent A: Water/TFA: 99.92:0.08, eluent B: acetonitrile/ TFA: 99.92:0.08; gradient B from 20% to 80% in 14 min, from 80% to 98% in 3 min). DMAP (8.5 mg, 0.2 mmol) in 0.5 ml of dry DMF was added, and the cartridge was shaked at room temperature for 6 h. After filtration of the solution the resin was rinsed with DMF (3 Â 5 ml), DCM (3 Â 5 ml) and TBME (3 Â 5 ml) and finally dried in vacuo.
The efficiency of loading (loading yield: 80%) was determined on 8.3 mg of resin by Fmoc removal analysis (treatment of the resin with piperidine 20% in DMF) and absorbance measurement at 301 nm (UV-vis Spectrophotometer Shimadzu).
General procedures for Fmoc deprotection and reductive amination
General procedures for trityl deprotection and cyclization
Trityl deprotection of 31 (0.04 mmol pre-swollen in DCM) was performed with TFA/triisopropyl silane (TIS)/DCM 10:5:85 (4 Â 30 min). Then the resin was filtered, rinsed with DCM and a solution of 10% Et 3 N in DMF was added.
After filtering and washing (DMF, DCM), a solution of CDI (60 mg, 0.37 mmol) dissolved in 1 ml dry DCM was introduced into the cartridge; the cyclization proceeded for 6 h at room temperature. Functionalized resin 32 was then rinsed with DCM (Â3), DMF (Â3), DCM (Â3), and TBME (Â3).
General procedures for the cleavage of hydroxamate derivatives 5a
The same procedure described for (R)-1a was followed. 77 mmol) and SOCl 2 (1.5 ml, 21 mmol) in dioxane for 2.5 h at 50°C) in 1 ml of dioxane was added to a freshly prepared solution of hydroxylamine, obtained by reaction between hydroxylamine hydrochloride (0.27 g, 3.85 mmol) and DIEA (690 ll, 3.85 mmol) in dioxane/water. After being stirred at room temperature overnight, the mixture was evaporated under reduced pressure and DCM and HCl 0.1 M solution were added. The organic layer was separated, and the aqueous one was extracted with DCM (2 Â 5 mL). The combined organic solutions were dried (MgSO 4 ), and evaporated to dryness.
A solution of the pure compound 33 (95.7% 220 nm, 91.2% 254 nm) (0.15 mg, 0.35 mmol) and DIEA (165 ll, 0.92 mmol) in 3 ml DMF/DCM (1:10) was added dropwise on chlorotrityl resin (Novabiochem) (160 mg, 0.23 mmol) pre-swollen in DCM. After shaking for 60 h at room temperature, the resin was filtered and rinsed first with DCM/MeOH/DIEA (17:2:1) (3 Â 5 min) and later with DCM (3 Â 5 ml), DMF (3 Â 5 ml), DCM (3 Â 5 ml) and TBME (3 Â 5 ml) and finally dried in vacuo. The efficiency of loading (loading yield: 60%) was determined on 2.8 mg of resin by Fmoc removal analysis (treatment of the resin with piperidine 20% in DMF) and absorbance measurement at 301 nm (UV-vis Spectrophotometer Shimadzu).
General procedures for Fmoc deprotection and Nsulphonylation
After Fmoc deprotection of (R)-34 with 20% piperidine in DMF for 20 min (Â2), the resin (70 mg, 0.07 mmol) was washed (2 Â DMF, 2 Â DCM), and DIEA (0.41 mmol, 73 ll) and a solution of bisphenylsulfonyl chloride (0.27 mmol, 68 mg) in 1.5 ml of dry DCM (11 mg, 0.09 mmol) were added dropwise. After shaking overnight at room temperature, the resin was filtered and rinsed with DCM (Â3), DMF (Â3), DCM (Â3) and TBME (Â3).
General procedures for allyl deprotection and cyclization
The same procedure described for (R)-14 was followed.
General procedures for cleavage of hydroxamates 6a
The crude product 6a was cleaved by treatment of 36a with 2.5 ml of TFA (5%) in DCM for 2 h at room temperature. The resin was then filtered and filtrate was evaporated under N 2 .
6a was further purified by semi-preparative RP-HPLC (C18, Nucleosil 300 mm Â 25 mm, 3 The synthesis of 7, 8 series was realized according to a common parallel strategy except for the coupling to NovaSynTGOH resin: N-Fmoc proline and N-Fmoc thioproline were loaded respectively via HATU and via fluoride. The subsequent synthetic steps were performed with the same experimental procedures.
General procedures for coupling of N-Fmoc proline to NovaSynTGOH
Example: Synthesis of 37.
A solution of Fmoc-L-proline (0.34 g, 1 mmol), HATU (0.38 g, 1 mmol), and DIPEA (348 ll, 2 mmol) in 2 ml of dry DMF/DCM (1:1) was dropped on the resin NovaSynTGOH (0.2 mmol).
The cartridge was rocked 12 h at room temperature. After filtration the resin was rinsed with DMF (3 Â 5 ml), DCM (3 Â 5 ml) and TBME (3 Â 5 ml) and finally dried in vacuo.
General procedures for coupling of N-Fmoc thiazolidine to NovaSynTGOH
Example: Synthesis of 38.
A solution of N-Fmoc thiazolidine (0.34 g, 1 mmol), HATU (0.38 g, 1 mmol), and DIPEA (348 ll, 2 mmol) in 2 ml of dry DMF/ DCM (1:1) was added dropwise on was added to NovaSynTGOH (0.2 mmol) after Fmoc deprotection via classical procedure (20% Piperidine in DMF for 20 min (Â2)). The cartridge was shaked for 12 h at room temperature. After filtration the resin was rinsed with DMF (3 Â 5 ml), DCM (3 Â 5 ml) and TBME (3 Â 5 ml) and finally dried in vacuo.
General procedures for N-sulphonylation of polymer bound proline/thioproline
Example: Synthesis of 40a. After Fmoc deprotection with 20% piperidine in DMF for 20 min (Â2), 39 (0.03 mmol) was washed (2 Â DMF, 2 Â DCM) and preswollen in 2 ml of THF in presence of DMAP (3.4 mg, 0.03 mmol). A solution of bisphenylsulphonylchloride (0.14 mmol) in 1 ml of dry DCM was added and the cartridge was rocked for 12 h at room temperature.
Then the resin was filtered and washed with MeOH (Â2), DMF (Â2), DCM (Â2) and TBME (Â2). MCPBA (31 mg, 0.17 mmol) in 4 ml of dry DCM was added to a DCM pre-swollen 40a (0.13 mmol) at 0°C. After rocking for 27 h at room temperature, the resin was filtered and washed with DCM (Â2), DMF (Â2), DCM (Â2) and TBME (Â2) and finally dried in vacuo.
General procedures for synthesis of oxidized derivatives 42
Example: Synthesis of 42a. MCPBA (37 mg, 0.213 mmol) in 4 ml of dry DCM was added to a DCM pre-swollen 41a (0.04 mmol) at 0°C. After rocking for 27 h at room temperature, the resin was filtered and washed with DCM (Â2), DMF (Â2), DCM (Â2) and TBME (Â2) and finally dried in vacuo.
General procedures for cleavage of hydroxamate derivatives 9 and 10
We follow the same procedure described for 8a. 
